- Home
- GSIW vs RVPH Comparison
GSIW vs RVPH Comparison
Compare GSIW & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- RVPH
- Stock Information
- Founded
- GSIW 2016
- RVPH 2006
- Country
- GSIW Hong Kong
- RVPH United States
- Employees
- GSIW N/A
- RVPH N/A
- Industry
- GSIW
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- RVPH Health Care
- Exchange
- GSIW Nasdaq
- RVPH Nasdaq
- Market Cap
- GSIW 27.2M
- RVPH 32.8M
- IPO Year
- GSIW 2023
- RVPH N/A
- Fundamental
- Price
- GSIW $1.75
- RVPH $0.40
- Analyst Decision
- GSIW
- RVPH Strong Buy
- Analyst Count
- GSIW 0
- RVPH 5
- Target Price
- GSIW N/A
- RVPH $9.00
- AVG Volume (30 Days)
- GSIW 2.6M
- RVPH 3.8M
- Earning Date
- GSIW 01-01-0001
- RVPH 08-13-2025
- Dividend Yield
- GSIW N/A
- RVPH N/A
- EPS Growth
- GSIW N/A
- RVPH N/A
- EPS
- GSIW N/A
- RVPH N/A
- Revenue
- GSIW $1,313,795.00
- RVPH N/A
- Revenue This Year
- GSIW N/A
- RVPH N/A
- Revenue Next Year
- GSIW N/A
- RVPH N/A
- P/E Ratio
- GSIW N/A
- RVPH N/A
- Revenue Growth
- GSIW N/A
- RVPH N/A
- 52 Week Low
- GSIW $0.35
- RVPH $0.30
- 52 Week High
- GSIW $12.30
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- GSIW 72.13
- RVPH 36.63
- Support Level
- GSIW $1.26
- RVPH $0.38
- Resistance Level
- GSIW $1.66
- RVPH $0.45
- Average True Range (ATR)
- GSIW 0.14
- RVPH 0.04
- MACD
- GSIW -0.02
- RVPH 0.01
- Stochastic Oscillator
- GSIW 92.25
- RVPH 58.54
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.